news aktuell GmbH

COUNTRY QUEEN IS THE FIRST KENYAN LICENSED BRANDED SERIES ON NETFLIX

Del
Country Queen, which premiered in 190 countries exclusively on Netflix 15th of July, is the first high-quality drama series from East Africa to reach a global audience! Launching as No. 1 TV Show in Kenya on Netflix for two weeks in a row, the series continues to gain stellar reviews, more traction and global recognition.

When death awakens a sleepy village, its past threatens to haunt the present.



(Berlin, Germany)
: COUNTRY QUEEN is a family drama series set in contemporary Kenya. The new, original drama series, first out of Kenya, is adding to the growing list of dynamic African content. The past and present collide in this David vs. Goliath story when a mining company threatens to destroy the rural home of AKISA MUTUNGA, an ambitious event planner, who is pitted against a deadly businesswoman, whose husband she is entangled with. Akisa finds herself in the midst of a love triangle, as she struggles to find her place in life by finding her true love and lost son.

Issues of land grabbing and exploitation form the tapestry against which the fractured personal lives and relationships of Country Queen's main characters play out. The fight for land becomes a fight for redemption and truth. The characters have to face the consequences of their own choices. The fictional story carries many elements of truth that speak to a range of issues such as family disputes, land ownership and exploitation that affect millions of people in Africa and worldwide.

Good Karma Fiction, together with ten up and coming Kenyan writers, developed the narrative. Good Karma Fiction's managing directors are the show runners of COUNTRY QUEEN. Season 1 was co-financed by German-French channel Arte/ZDF, German Government/DW Akademie, a private investor and Netflix.

https://www.countryqueen.tv/
#CountryQueenKenya

Kontakter

Waltraud Ehrhardt
ehrhardt@goodkarmafiction.com

Bilder

Om news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Følg pressemeldinger fra news aktuell GmbH

Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra news aktuell GmbH

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release

Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized

Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release

youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU

I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye